Novartis Pharmaceuticals

This early-stage trial is testing whether combining the experimental drug EGF816 with other targeted cancer drugs is safe and might help control advanced lung cancer that has specific EGFR genetic mutations. The study involves about 105 adults whose cancer has progressed despite …

This study is testing whether an experimental drug called remibrutinib works better than an existing medication (teriflunomide) for people with relapsing multiple sclerosis. About 1,000 participants will take one of these medications for up to 30 months, with the option to contin…

This study is testing whether a new targeted radiation drug (177Lu-PSMA-617) works better than switching to a different standard hormone therapy for men with advanced prostate cancer that has spread and stopped responding to their first hormone treatment. The drug is designed to …

This study is testing a new radioactive drug called [225Ac]Ac-PSMA-R2 in men with advanced prostate cancer that has spread. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for men whose cancer has progressed despite previous hormone therapy and…

This study observes people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) early in their disease journey leads to better outcomes than starting it later. It follows 106 patients for two years, comparing those who start the drug soon…

This study is testing if a medication called inclisiran, when added to standard cholesterol-lowering statin therapy, can slow or reduce the buildup of fatty plaque in the heart's arteries. It involves about 610 adults with early-stage coronary artery disease who have not yet had …

This study allows patients with advanced solid tumors who are already benefiting from the cancer drug ribociclib to continue receiving it after their original clinical trial has ended. The purpose is to provide continued access to treatment while monitoring safety. Participants m…

This Phase 3 trial is testing whether an oral medication called iptacopan can safely and effectively treat atypical hemolytic uremic syndrome (aHUS), a rare disease that damages blood vessels and kidneys. The study involves about 50 adult patients who have not previously received…

This study is observing how well the drug ofatumumab (brand name Kesimpta) works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday Italian clinics. It will follow 379 patients newly starting this treatment for 12 months to see its effects on relapses, disa…

This study is testing whether a new drug called crizanlizumab can safely reduce the number of painful vaso-occlusive crises (VOCs) in people with sickle cell disease. It involved about 240 teens and adults who have a history of these painful episodes. Participants received either…

This study is monitoring the safety and effectiveness of brolucizumab, an eye injection, for diabetic macular edema (DME) in a real-world setting. It involves 63 adult patients in India who have vision problems due to DME and are already scheduled to receive this treatment. Resea…

This study compares two oral medications, asciminib and nilotinib, for adults newly diagnosed with a specific type of chronic leukemia (Ph+ CML). The main goal is to see which drug is better tolerated, meaning it causes fewer side effects that make people stop taking it. Research…

This study aims to collect long-term safety information on the drug sabatolimab for patients with certain blood cancers. It is for patients who have already been receiving sabatolimab in a previous Novartis study and are still benefiting from it. The main goal is to monitor for a…

This study is testing whether adding an investigational drug called iptacopan to standard treatment helps people with active ANCA-associated vasculitis. The goal is to achieve and maintain remission—a state with no disease activity—for longer periods while reducing the need for s…

This study is testing the safety and effectiveness of a two-drug combination (alpelisib and fulvestrant) for Japanese men and postmenopausal women with a specific type of advanced breast cancer. The cancer must have a PIK3CA mutation and have worsened after standard hormone thera…

This study is testing whether combining a targeted radiation drug (lutetium) with a hormone therapy drug (ARPI) works better than the radiation drug alone for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. About 420 partic…

This study is testing a new oral drug, JDQ443, against the standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It's for adults whose cancer has worsened after trying standard treatments like pl…

This study is following 4 patients for 15 years after they received an experimental gene therapy for sickle cell disease. The therapy involves editing a patient's own blood stem cells to produce fetal hemoglobin, which can help control the disease. Researchers are monitoring long…

This large Phase 3 study is testing whether a new oral drug called remibrutinib works better and is as safe as an existing standard oral medication (teriflunomide) for adults with relapsing multiple sclerosis (RMS). About 1011 participants will take one of the two drugs for up to…

This study is for people with relapsing-remitting multiple sclerosis (MS) who have been stable on their current medication for at least a year. It aims to find out if switching to a different drug called ofatumumab is better at keeping the disease quiet than staying on their curr…

This study is testing whether adding a new drug called ianalumab to a standard treatment (eltrombopag) can help adults with a persistent autoimmune bleeding disorder (ITP) maintain safe platelet levels for a longer time. It is for people whose ITP did not respond well enough to o…

This study is observing how well the approved cancer drug Lutathera works for adults with advanced neuroendocrine tumors of the gut or pancreas in real-world medical practice. Researchers are following 164 patients for up to 3 years to see how long the treatment keeps the cancer …

This study is observing 600 Belgian patients with heart disease who are taking the cholesterol-lowering injection inclisiran along with their standard medications. Researchers are tracking how well the drug lowers 'bad' cholesterol (LDL-C) in real-world doctor's offices, not a co…

This study is testing whether a single dose of an experimental drug called TIN816 can help improve kidney function in hospitalized adults with severe infections (sepsis) that have caused sudden kidney injury. Researchers will compare three different doses of TIN816 against a plac…

This study follows patients with Sjögren's syndrome for up to 8 years to check the long-term safety of the medication ianalumab. It includes 612 participants who previously completed one-year trials of the same drug. The research aims to see if continued treatment helps control d…

This study is monitoring the long-term safety of Leqvio, a cholesterol-lowering injection, in real-world medical practice in Japan. It will follow 585 patients with high cholesterol or inherited high cholesterol conditions for up to two years after starting treatment. The main go…

This study is testing whether a single infusion of a personalized immune cell therapy (tisagenlecleucel) works better than current standard drug treatments for adults with follicular lymphoma that has come back or stopped responding to prior therapies. It involves about 109 parti…

This large, late-stage trial is testing whether adding a drug called ribociclib to standard hormone therapy can better prevent cancer from returning in people with a common type of early-stage breast cancer. It enrolled over 5,000 men and women who had surgery and are at higher r…

This study follows teenagers with a genetic condition causing very high cholesterol (familial hypercholesterolemia) who previously took the drug inclisiran in earlier trials. The main goal is to monitor the long-term safety and side effects of continued treatment. It also provide…

This study is observing children and teens (ages 6-17) with moderate-to-severe plaque psoriasis who are starting treatment with the drug secukinumab. The main goal is to see how long patients stay on the medication, how effective it is at clearing their skin, and what side effect…

This study follows children and teens who are already taking the medications dabrafenib and/or trametinib for various types of brain tumors. The main goal is to monitor their long-term health, safety, and development while they continue treatment. Researchers will track side effe…

This study is following patients with a rare genetic overgrowth condition (PROS) who are already taking the drug alpelisib. It aims to monitor the long-term safety and effectiveness of the medication over five years. The study is only for people who were in a previous clinical tr…

This study is testing whether adding a new drug called ianalumab to standard steroid treatment helps adults with primary immune thrombocytopenia (ITP) maintain safer platelet counts and reduce bleeding risk. The trial involves 226 participants who will receive either ianalumab or…

This study is testing whether a new injectable drug called inclisiran can safely lower 'bad' LDL cholesterol in Asian adults who have heart disease or are at high risk for it. Participants are already taking the highest dose of statin pills they can tolerate. The goal is to see i…

This is the first study in people to test the safety and find the right dose of an experimental drug called IDH305. It is for patients with advanced cancers that have a specific genetic change called an IDH1 mutation. The main goal is to see how much of the drug patients can safe…

This study is testing a new targeted radiation drug called 177Lu-PSMA-617 for men in Japan with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The drug is designed to find and deliver radiation directly to prostate cancer cells…

This large, late-stage trial is testing whether a new drug called pelacarsen can reduce the risk of major heart problems like heart attacks and strokes. It involves over 8,300 people who already have heart disease and have high levels of a specific blood fat called lipoprotein(a)…

This study is testing whether a new drug called ianalumab can help people with warm autoimmune hemolytic anemia (wAIHA) who haven't responded well to at least one previous treatment. It will compare two different doses of ianalumab against a placebo in 90 participants to see if i…

This study follows adults with chronic spontaneous urticaria (CSU), also known as chronic hives, who previously took remibrutinib in earlier trials. It aims to collect long-term safety data and see if the treatment continues to control symptoms when some participants temporarily …

This study allows patients with ALK-positive cancers who are already taking ceritinib in a Novartis trial to continue receiving the drug if their doctor believes they're benefiting from it. It primarily monitors the drug's safety and side effects in these patients over the long t…

This study is testing whether adding a monthly injection called ianalumab to standard lupus treatment helps control the disease better than standard treatment alone. Researchers are enrolling 288 people with active systemic lupus erythematosus to see if the drug reduces disease f…

This study is testing if adding a cholesterol-lowering injection called Inclisiran to standard statin pills can better reduce the fatty buildup (plaque) in heart arteries of people who recently had a heart attack. About 318 participants in China will receive either the drug combi…

This study is testing whether a new drug called ianalumab can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 276 participants will receive either the drug or a placebo as a monthly injection for nearly a year. Researchers will measure changes…

This study is testing an experimental immune therapy called tisagenlecleucel (a type of CAR-T cell therapy) in children and young adults (ages 1-25) with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The treatment is for patients who still show small amounts of cancer ce…

This is the first-ever human study of an experimental gene therapy called CPK850 for a rare, inherited form of vision loss called RLBP1 retinitis pigmentosa. The main goals are to find a safe dose and see if a single injection into the eye can help improve patients' vision, espec…

This study is testing whether adding a new radioactive drug called [177Lu]Lu-DOTA-TATE to standard chemotherapy and immunotherapy can better control an aggressive type of lung cancer. It aims to find a safe dose and see if this combination helps patients live longer compared to s…

This study is checking the safety and effectiveness of the drug asciminib for adults in India with a specific type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (CML). It is for patients whose cancer has not responded well to at least two other …

This study is testing an investigational drug called MAS825 to see if it can safely prevent disease flares in people with rare, genetic autoinflammatory diseases like NLRC4-GOF and XIAP deficiency. The trial involves about 17 patients, including infants and adults, who have one o…

This study follows patients with tuberous sclerosis complex (TSC) who have seizures that are hard to control with standard medications. It monitors the long-term safety of the drug everolimus over approximately 10 years in about 206 patients who benefited from it in a previous tr…

This study is testing whether a drug called pelacarsen can safely lower high levels of a protein called Lp(a), which is linked to heart disease. It focuses on Black/African American and Hispanic adults who already have heart disease and are receiving standard care. Participants r…

This program provided access to two targeted drugs, trametinib and dabrafenib, for adults with advanced, BRAF mutation-positive melanoma who had no other treatment options available. It was a compassionate use program, meaning it offered the drugs outside of regular clinical tria…

This study is checking the safety and effectiveness of the drug everolimus for Taiwanese adults with tuberous sclerosis complex who have non-cancerous kidney tumors called angiomyolipomas. It will follow a small group of eligible patients for about a year to see if the drug shrin…

This study allows patients with gastrointestinal stromal tumors (GIST) or chronic myeloid leukemia (CML) who are already benefiting from the drug imatinib to continue receiving it. The main goal is to collect long-term safety information by monitoring patients for side effects. I…

This study provides continued access to the cancer drug capmatinib for patients who were already receiving it in previous Novartis trials and are still benefiting from it. The main goal is to monitor the long-term safety of the treatment in 29 patients with advanced solid tumors.…

This study allows patients who benefited from previous clinical trials of ruxolitinib (alone or with panobinostat) to continue receiving their treatment while researchers monitor long-term safety. The study includes 279 patients with various blood conditions like myelofibrosis an…

This study is testing an investigational oral medication called remibrutinib for adults with chronic inducible urticaria (CINDU), a condition where hives are triggered by specific physical stimuli like touch, cold, or heat. The main goal is to see if the drug is more effective th…

This large, late-stage trial is testing if adding a new targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy works better than standard therapy alone for men whose prostate cancer has recently spread. The drug is designed to seek out and deliver radiation directly…

This study aims to find out if people with moderate to severe hidradenitis suppurativa (HS) who improved on a medication called secukinumab should continue treatment or can safely take a break. About 700 participants who already responded to the drug in earlier studies will be ra…

This is an early-stage study testing a new drug called DKY709, both alone and combined with another drug (PDR001), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find safe doses and understand side effects. Researcher…

This study is testing the safety and effectiveness of adding a drug called midostaurin to standard chemotherapy for children newly diagnosed with a specific genetic type of acute myeloid leukemia (AML). It involves 22 children and aims to see if this combination can better contro…

This is a first-in-human study to find a safe dose and schedule for an experimental drug called PIT565. It is for adults with advanced B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to at least two prior treatments. The main …

This program provided special access to the drug siponimod for adults with a specific, active form of progressive multiple sclerosis (SPMS) who had no other satisfactory treatment available. It was not a standard clinical trial but a managed access plan, allowing doctors to reque…

This study tested a new type of targeted radiation therapy for Chinese men with advanced prostate cancer that has spread and stopped responding to standard hormone and chemotherapy treatments. The treatment uses a radioactive drug that seeks out and delivers radiation directly to…

This large, late-stage study is testing whether a new drug called ianalumab can help control the disease and reduce symptoms for people with active Sjogren's syndrome. About 500 participants will receive injections of either the drug or a placebo for nearly a year to see if it sa…

This study is testing a new oral medication called asciminib against standard first-line treatments for adults newly diagnosed with a specific type of chronic myeloid leukemia (CML). The goal is to see if asciminib is more effective at controlling the disease and if patients can …

This study is testing whether the drug BION-1301 can help adults with IgA nephropathy, a kidney disease that can lead to kidney failure. About 383 participants will receive either the drug or a placebo injection every two weeks for two years. The main goal is to see if the drug r…

This study is testing a new type of personalized immune cell therapy called rapcabtagene autoleucel (a CAR-T cell therapy) for adults with several aggressive or returning blood cancers. The main goals are to find a safe and effective dose and to see if the therapy can shrink or e…

This is an early-stage study to find a safe dose of a new drug called KFA115, given alone or with an existing immunotherapy (pembrolizumab), for people with advanced cancers that have stopped responding to standard treatments. The main goal is to check for side effects and determ…

This study is testing five different new drugs to see if they can help people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. It involved 248 participants who received either one of the drugs or a placebo for 16 weeks. The main goal was to see if …

This study is testing two new experimental drugs (LEE011 and BYL719) combined with the standard hormone therapy letrozole for women with advanced ER+ breast cancer. The main goals are to find the safest and most effective doses and to see how well the combinations work to control…

This study continues monitoring the safety of spartalizumab, an experimental cancer treatment, for patients who were already receiving it in previous Novartis trials. It allows 120 patients with advanced solid tumors to keep getting the treatment while researchers track side effe…

This study observes how well adults with chronic myeloid leukemia stay on Scemblix treatment after trying at least two other therapies. It follows 201 patients in France for 15 months to see if they remain on the medication and how their disease responds. The goal is to understan…

This was a special access program for the drug capmatinib. It was designed for patients with a specific, advanced form of non-small cell lung cancer who had no other treatment options and could not join a standard clinical trial. The program provided the drug outside of a trial s…

This study is checking how safe and effective the drug Egaten is for treating fascioliasis, a parasitic liver infection. About 300 adults and children aged 6 and older with the infection will take two doses of the medicine 12 hours apart. Researchers will monitor patients for sid…

This study is testing if a new, less frequent dosing schedule for the MS drug ofatumumab works as well as the current approved schedule. It will involve about 196 adults with relapsing forms of MS. The main goal is to see if the new schedule keeps enough medicine in the body to c…

This study aims to find out if people with non-radiographic axial spondyloarthritis (a type of inflammatory back disease) need to continue taking the drug secukinumab long-term after their symptoms go away. It will enroll 240 adults whose disease is in remission. The main goal is…

This large, late-stage trial is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better for people newly diagnosed with myelofibrosis, a serious bone marrow cancer. The study will see if the combination shrinks enlarged spleens mor…

This study tested whether adding the drug alpelisib to standard therapy helps control advanced HER2-positive breast cancer that has a specific genetic mutation (PIK3CA). It was a Phase 3 trial for patients whose cancer had not progressed after initial chemotherapy. The study was …

This study is observing whether a combination of two drugs, dabrafenib and trametinib, can help prevent melanoma skin cancer from returning in Chinese patients who have had it surgically removed. The treatment is given for one year to patients whose cancer has a specific genetic …

This study allows patients with metastatic breast cancer who are already benefiting from ribociclib treatment in previous Novartis trials to continue receiving the medication. The main goal is to monitor long-term safety while providing continued access to the drug. Participants …

This study aims to find out if two newer MS medications (ofatumumab and siponimod) work as well as or better than an existing one (fingolimod) in controlling relapses for children and teens aged 10-17. It will follow about 120 young patients for up to 7 years to compare how often…

This early-stage study is testing a new treatment called YTB323, a type of CAR-T cell therapy, for people with severe lupus that hasn't responded to other strong medications. The main goals are to see if the treatment is safe and if it can reduce lupus disease activity. Researche…

This study is testing a new drug called JDQ443, both alone and in combination with other treatments, for patients with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find safe doses and see if the treatments can shrink tumors. It…

This large study is testing if a new drug called inclisiran can help prevent serious heart problems in people who already have heart disease. Over 17,000 participants will receive either the drug or a placebo as a shot every six months, on top of their standard cholesterol medica…

This early-stage study is testing a new radioactive drug called [177Lu]Lu-DOTA-TATE for adults with glioblastoma, a fast-growing brain cancer. For newly diagnosed patients, the drug is given alongside standard radiotherapy and chemotherapy. For patients whose cancer has returned,…

This early-stage study is testing a new oral drug called DFV890 in adults with certain blood and bone marrow disorders, including some forms of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The main goals are to find a safe and tolerable dose and to …

This study is testing whether the drug eltrombopag can help Japanese adults with a specific type of lower-risk myelodysplastic syndrome (MDS) become independent from needing regular platelet transfusions. It compares the drug against a placebo in a small group of 36 participants.…

This study aims to collect long-term safety and effectiveness data for the drug ofatumumab in people with relapsing multiple sclerosis (MS). It follows nearly 1,900 patients who previously participated in a Novartis MS study to monitor their health over an extended period. The re…

This study aims to find out which of two existing multiple sclerosis (MS) medications works better and is safer for children and teenagers aged 10-17. About 240 young patients will take either a daily pill (fingolimod) or a weekly injection (interferon beta-1a) for two years, wit…

This study is observing how well a standard breast cancer drug combination works for patients aged 65 and older during their normal medical care in Russia. It aims to see how the treatment affects patients' quality of life, how long the cancer stays under control, and what side e…

This early-stage study is testing a personalized radiation treatment for men with metastatic neuroendocrine prostate cancer, an aggressive form of the disease. Doctors first scan each patient's tumors to see which of three specific targets is most present, then deliver a matching…

This study is testing several combinations of an experimental drug called LXH254 with other cancer medications for people with advanced melanoma that has spread and hasn't responded to previous treatments. The research aims to see if these combinations can shrink tumors and contr…

This study is testing whether the drugs dabrafenib and trametinib can help control advanced thyroid cancer that has a specific genetic change (BRAF V600E mutation) and has stopped responding to radioactive iodine and other targeted therapies. It is a large, late-stage (Phase 3) t…

This study is testing if a new pill called remibrutinib can better control chronic hives in adults when standard allergy medicines don't work. It will compare the pill to a currently approved injection treatment (omalizumab) over one year, with an option for a second year on the …

This study is testing whether adding the drug alpelisib to standard fulvestrant treatment helps control advanced breast cancer better than fulvestrant alone. It is for men and postmenopausal women whose cancer has a specific genetic change (PIK3CA mutation) and has worsened after…

This study is testing a targeted radiation drug called lutetium vipivotide tetraxetan to see if it can better control advanced prostate cancer. It will involve about 80 men whose cancer has stopped responding to standard hormone therapy but hasn't visibly spread on standard scans…

This study is testing the safety and initial effectiveness of combining two drugs, ceritinib and nivolumab, for adults with advanced ALK-positive non-small cell lung cancer. It aims to find the best dose and see if the combination helps shrink tumors. The trial involves 57 partic…

This early-stage study is testing a new radioactive drug called [177Lu]Lu-NeoB for glioblastoma, a very aggressive brain cancer. For newly diagnosed patients, the drug is added to standard radiation and chemotherapy. For patients whose cancer has returned, it's given alone. The m…

This study aimed to test two new radioactive drugs (AAA602 and AAA802) in men with high-risk prostate cancer that had not spread far. The drugs were given before surgery to remove the prostate, with the goal of killing more cancer cells and lowering the chance of the cancer comin…

This large, late-stage study is testing whether adding a new injectable drug called ianalumab to standard lupus care can better control the disease. About 436 people with active lupus will receive either the real drug or a placebo shot monthly or quarterly for over a year. The ma…

This study is testing new drug combinations for people with advanced solid tumors that have a specific genetic change called KRAS G12C. It focuses on patients with non-small cell lung cancer or colorectal cancer who have already tried standard treatments. The main goals are to fi…

This study is observing how well a cholesterol-lowering injection called inclisiran works for people in their regular doctor's care. It will follow about 850 adults with high cholesterol for up to two years to see how much their 'bad' cholesterol drops and how consistently they g…

This study is testing whether the drug alpelisib can safely reduce abnormal tissue overgrowth in people with a rare genetic condition called PROS. It involves about 200 children and adults. For the first 16 weeks, some participants receive the drug while others receive a placebo,…

This program provided access to the drug ruxolitinib for polycythemia vera patients who couldn't tolerate standard treatments. It was designed for compassionate use when other options had failed. The program is no longer accepting new patients.

This study is testing a drug called asciminib for adults with chronic phase chronic myeloid leukemia (CML). It includes two groups: patients whose first treatment didn't work well or caused side effects, and newly diagnosed patients. The goal is to see if asciminib can effectivel…

This study observes how well two different treatment approaches work for people with advanced HR+HER2- breast cancer in everyday Russian medical practice. It follows 376 patients who have already started treatment with either ribociclib plus hormone therapy or standard chemothera…

This study tested whether adding the drug alpelisib to standard chemotherapy could better control advanced triple-negative breast cancer in patients with specific genetic changes in their tumors. It involved 137 patients and was a Phase 3 trial, but recruitment was halted early. …

This early-stage trial is testing a new oral drug called HRO761, both alone and combined with other cancer therapies, for people with advanced solid tumors that have specific genetic changes (MSI-High or dMMR). The main goals are to find safe and effective dose levels and to see …

This study observes how well the MS medication Kesimpta (ofatumumab) works for 107 Swiss patients in real-world medical care over 12 months. Researchers will track whether patients show no signs of disease activity, monitor treatment adherence, and measure how the treatment affec…

This study is testing an experimental drug called JDQ443 as the first treatment for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The trial will enroll 95 participants to see how well the drug shrinks tumors and how safe it i…

This study is testing whether an experimental drug called VHB937 can slow the progression of early-stage ALS (Lou Gehrig's disease). It will involve 251 adults who have had ALS symptoms for less than two years. Participants will receive either the drug or a placebo for 40 weeks, …

This study is a long-term extension for people who completed an earlier trial of votoplam for Huntington's disease. It aims to monitor the safety and effects of the drug over an additional 54 months. All participants will receive the active drug, and researchers will track side e…

This study is testing if a new, single auto-injector pen delivers the same amount of the drug ianalumab into the body as two separate pre-filled syringes. It involves 155 adults with rheumatoid arthritis, lupus, or Sjögren's disease. The main goal is to see if the drug levels in …

This study is comparing a newer cholesterol-lowering injection called inclisiran against standard care for patients in China with coronary heart disease. It aims to see if inclisiran is more effective at lowering 'bad' cholesterol (LDL-C) over one year in a real-world setting. Th…

This early-stage study is testing a new oral medication called IAG933 in adults with advanced cancers, including mesothelioma, that have specific genetic changes. The main goals are to find a safe dose and see how well the body handles the drug. Researchers will also look for ear…

This study is testing an experimental drug called ianalumab for adults with primary immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets, increasing the risk of bleeding. It is for people whose ITP hasn't been controlled well by at least two …

This large study is testing whether a medication called inclisiran, given as an injection every six months, can prevent serious heart problems like heart attacks and strokes in people at high risk who haven't had one yet. About 14,000 participants will receive either the real dru…

This study aims to understand how patients with hidradenitis suppurativa (HS) experience their symptoms after starting a medication called secukinumab. Researchers will follow 192 adults in France for up to two years, asking them to report on pain, oozing, and odor. The goal is t…

This study aims to identify factors that can predict when patients with a specific blood cancer (high-risk polycythemia vera) might develop dangerous blood clots. Researchers will observe 242 patients who are already receiving standard treatment for their condition. They will col…

This study aims to understand how a multiple sclerosis (MS) treatment called ofatumumab affects patients' quality of life in real-world settings. It will follow 302 adults in France for up to 12 months after they start the treatment, as prescribed by their neurologist. The main g…

This study aims to understand how doctors in Germany adjust the dose of the approved drug secukinumab for adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. It will observe 424 patients over two years during their routine treatment, tracking w…

This study aims to understand how real-world medical care in Romania aligns with established treatment guidelines for a common type of heart failure. Researchers will analyze existing, anonymous health records of 500 adult patients who were prescribed the medication Entresto. The…

This study observes how the already-approved cancer drug ribociclib, combined with hormone therapy, works for women with advanced breast cancer in real-world French clinics. Researchers will follow over 1,000 patients for several years to see how long the treatment controls the c…